Clinical data | |
---|---|
Pronunciation | /zaɪˈkɒnoʊtaɪd/ zy-KON-oh-tyd |
Other names | SNX–111 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Intrathecal – directly into cerebrospinal fluid by a catheter |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 50% |
Elimination half-life | 2.9 to 6.5 hours |
Excretion | <1% urine |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.212.174 |
Chemical and physical data | |
Formula | C102H172N36O32S7 |
Molar mass | 2639.14 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Ziconotide, sold under the brand name Prialt, also called intrathecal ziconotide (ITZ) because of its administration route, is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus, a cone snail, it is the synthetic form of an ω-conotoxin peptide.[2] It is 1,000 times as powerful as morphine.[citation needed]
In December 2004 the Food and Drug Administration approved ziconotide when delivered as an infusion into the cerebrospinal fluid using an intrathecal pump system.